BioWisdom Joins MDL® Isentris® Alliance
News May 22, 2007
Elsevier MDL and BioWisdom Ltd. have formed a strategic alliance to connect the MDL® Isentris® discovery informatics system with BioWisdom’s Healthcare Intelligence platform. The first development under this agreement will make BioWisdom’s SRS life sciences information platform accessible via Isentris.
“This agreement brings together the industry standards in biological and chemical data management,” said Gordon Baxter, CEO of BioWisdom. “The cross-connection of MDL and BioWisdom software and content supports BioWisdom’s strategy to provide the end user with the fullest possible insight and analysis, ultimately leading to better decision making. We look forward to further combinations of products, as we continue to enhance our software offering to customers.”
“Integrating the wide variety of biology data in BioWisdom’s SRS system with the structured chemical data already available in MDL Isentris is a major step in bringing together valuable, multi-disciplinary information for life sciences researchers,” said Lars Barfod, President and CEO of Elsevier MDL. “The addition of the important SRS system is a key milestone in making Isentris the platform of choice for integrating critical information across the entire life sciences domain.”
BioWisdom’s integrated set of software products includes OmniViz, Sofia and SRS. These tools exploit ontology-based Intelligence Networks on an enterprise scale, enabling discovery and development scientists to build, analyze and visualize semantically normalized knowledge bases derived from hundreds of different information sources.
BioWisdom’s SRS platform is the industry standard for providing access to diverse life sciences information including genetic, protein, expression, pathway, molecular and clinical data from public and proprietary sources.
As a strategic partner in the MDL® Isentris® Alliance, BioWisdom will work with Elsevier MDL to create connections between these life sciences information tools and MDL solutions.
The recently released MDL Isentris 2.0 system integrates information and applications into workflows, providing a research environment where scientists can access internal and external data on demand, collaborate with colleagues, analyze data and gain insight to make informed decisions. Along with features and performance improvements, the new release includes .NET controls for developing and extending custom applications.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.